Dashboard
Dividend Tracker
My Portfolio
Portfolios
Investors
Analysts
Community
Calendars
Economic Calendar
Dividend Calendar
Earnings Calendar
Splits Calendar
IPO Calendar
Markets
Stocks
Indices
Forex
Crypto
Commodities
News
Sign Up
Sign In
Your search results will appear here.
Light Mode
Dark Mode
Sign Up
Sign In
Xuanzhu Biopharmaceutical Co., Ltd. (2575)
Market Open
7 Aug, 08:00
HKEX
All
(2)
DE
(1)
HK
(1)
HKEX
Primary
XFRA
12.
48
HKD
+0.39
+3.2258%
HKD
32.63B
Market Cap
-
P/E Ratio
-
Div Yield
399,489
Volume
-
Eps
12.09
HKD
Previous Close
Watching
Watch
Add Transaction
Day Range
11.88
12.65
Year Range
10.6
96.9
Want to track
2575
and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Get Started For Free
Overview
Statistics
Historical Data
Xuanzhu Biopharmaceutical Co., Ltd. (2575) Statistics
Valuation metrics
Market Cap
32.63B
Enterprise value
5.7B
Trailing P/E (ttm)
-24.47
Forward P/E
-
PEG ratio
-0.24
Price/Sales (ttm)
115.12
Price/Book (mrq)
4.24
Enterprise Value/Revenue
101.5
Enterprise Value/EBITDA
-25.84
Overview
Shares outstanding
517.95M
Float
142.8M
Shares short
-
% Held by insiders
0.85%
% Held by institutions
0.01%
Average volume (10 days)
477.12K
Average volume (90 days)
1.6M
Price summary
52-Week low
10.6
52-Week high
96.9
Beta
-
50-Day moving average
12.92
200-Day moving average
32.25
Financials
Fiscal year
Fiscal year ends
31 Dec 2025
Most recent quarter (mrq)
31 Dec 2025
Profitability
Profit margin
-4.74%
Operating margin
-4.51%
Operational effectiveness
Return on assets
-0.15%
Return on equity
-0.21%
Income Statement
Revenue (ttm)
59.93M
Revenue per share (ttm)
0.11
Quarterly revenue growth (yoy)
1.41%
Gross profit (ttm)
29.77M
EBITDA
-238.05M
Net income to common (ttm)
-284.21M
Diluted EPS (ttm)
-0.51
Quarterly earnings growth (yoy)
-
Balance Sheet
Total cash (mrq)
755.09M
Total cash per share (mrq)
1.48
Total debt (mrq)
748.99K
Total Debt/Equity (mrq)
0
Current ratio (mrq)
3.75%
Book value per share (mrq)
2.95
Cash Flow
Cash flow statement
-243.06M
Levered free cash flow (LFCF)
-197.58M